MARKET

CLSD

CLSD

Clearside Biomed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.310
+0.010
+0.77%
After Hours: 1.310 0 0.00% 16:00 05/25 EDT
OPEN
1.300
PREV CLOSE
1.300
HIGH
1.340
LOW
1.280
VOLUME
153.38K
TURNOVER
0
52 WEEK HIGH
7.73
52 WEEK LOW
1.280
MARKET CAP
78.80M
P/E (TTM)
-45.6446
1D
5D
1M
3M
1Y
5Y
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -333.33% and 96.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/11 21:25
Clearside Biomedical: Q1 Earnings Insights
Clearside Biomedical (NASDAQ:CLSD) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Benzinga · 05/11 20:55
Clearside Biomedical Says Poster Presentation At ARVO 2022 Annual Meeting Demonstrates Versatility Of Suprachoroidal Delivery Technology
Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology - Multiple Poster Presentations on XIPERE® and Gene Therapy Delivery Utilizing
Benzinga · 05/05 11:33
Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11, 2022
ALPHARETTA, Ga., April 29, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fir...
GlobeNewswire · 04/29 11:05
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Stock Jumps 24.5%: Will It Continue to Soar?
Bicycle Therapeutics PLC Sponsored ADR (BCYC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks · 04/11 11:44
Clearside Biomedical to Present at the Needham Virtual Healthcare Conference
ALPHARETTA, Ga., April 06, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Thomas...
GlobeNewswire · 04/06 11:05
BRIEF-Bausch + Lomb And Clearside Biomedical Announce The U.S. Commercial Launch Of Xipere
reuters.com · 03/28 11:05
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), and Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), a biopharmaceutical company revolutionizing the delivery of therapies to the...
CNW Group · 03/28 10:59
More
No Data
Learn about the latest financial forecast of CLSD. Analyze the recent business situations of Clearside Biomed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

16.67%Strong Buy
50.00%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CLSD stock price target is 10.60 with a high estimate of 17.00 and a low estimate of 7.00.
High17.00
Average10.60
Low7.00
Current 1.310
EPS
Actual
Estimate
-0.030.080.180.28
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 94
Institutional Holdings: 22.40M
% Owned: 37.24%
Shares Outstanding: 60.15M
TypeInstitutionsShares
Increased
14
1.41M
New
9
660.64K
Decreased
22
2.49M
Sold Out
16
4.22M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Non-Executive Chairman/Independent Director
William Humphries
President/Chief Executive Officer/Director
George Lasezkay
Chief Financial Officer
Charles Deignan
Other
Thomas Ciulla
Director
Benjamin Yerxa
Independent Director
Richard Croarkin
Independent Director
Jeffrey Edwards
Independent Director
Nancy Hutson
Independent Director
Christy Shaffer
Independent Director
Clay Thorp
No Data
No Data
About CLSD
Clearside Biomedical, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Its proprietary suprachoroidal space (SCS) microinjector targeting SCS offers access to the macula, retina and choroid where sight-threatening disease often occurs. The SCS injection platform is an inherently flexible, in-office, non-surgical procedure intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations. The Company’s suprachoroidal injection platform is a patented approach for delivering pharmacotherapy to the back of the eye through SCS. The Company’s lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection.

Webull offers kinds of Clearside Biomedical Inc stock information, including NASDAQ:CLSD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLSD stock methods without spending real money on the virtual paper trading platform.